Bristol-Myers Executive Accused of Insider Trading

Bristol-Myers Squibb Co. executive Robert Ramnarine was charged with insider trading for making $311,361 in illegal profit by buying stock options in three companies targeted for acquisition.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.